Status:
UNKNOWN
Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE)
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Fibromyalgia
Systemic Lupus Erythematosus
Eligibility:
FEMALE
18-80 years
Brief Summary
Polyunsaturated omega-3 fatty acids (ω3 PUFAs) are essential nutrients. Studies indicate that the incidence of Major Depression (MD) is inversely related to the consumption of fish (which are rich in ...
Detailed Description
Background: Fibromyalgia is a common, chronic pai n disorder that is recognized by the American College of Rheumatology as a distinct clinical entity (1). In addition to the core feature of long-term...
Eligibility Criteria
Inclusion
- Inclusion criteria (fibromyalgia):
- Female adults, 18-80 years old
- Diagnosis of fibromyalgia per ACR1990 criteria (1)
- Inclusion criteria (SLE):
- Diagnosis of SLE according to the ACR criteria
Exclusion
- Exclusion criterion (for fibromyalgia patients):
- Other rheumatic disease (RA, SS, symptomatic osteoarthritis etc.)
- Other inflammatory disease associated with musculoskeletal pain (e.g. IBD)
- Painful neuropathic conditions (diabetic neuropathy, post-herpetic neuralgia etc.)
- Pregnancy or lactation
- Significant fluctuation in pain level over the previous \~3 months
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2013
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01460680
Start Date
November 1 2011
End Date
June 1 2013
Last Update
October 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky Medical Center Institute of Rheumatlogy
Tel Aviv, Israel